<DOC>
	<DOCNO>NCT00679549</DOCNO>
	<brief_summary>This study evaluate whether treat sleep apnea hospital would help heart failure , assist recovery worsen heart function current clinical standard wait treatment subject leave hospital . Heart failure affect 2 % US population cardiovascular disorder rise incidence . The annual cost CHF 2005 $ 27.9 billion , large percentage cost hospitalization exacerbation CHF . Half patient CHF form sleep apnea , go undiagnosed . Patients CHF OSA benefit treatment CPAP outpatient . The society benefit develop recommendation approach sleep apnea hospitalize CHF patient , may shorten length stay , improve functional status discharge patient , reduce rehospitalizations .</brief_summary>
	<brief_title>The Role Sleep Apnea Acute Exacerbation Heart Failure</brief_title>
	<detailed_description>Target population : Patients admit OSU Heart Hospital ADHF routinely undergo cardiorespiratory sleep study identify OSA . Patients ADHF newly diagnose OSA hospital stay eligible study . Enrollment : Given presence significant previously unrecognized OSA 62 % patient hospitalize ADHF , expect need screen 270 patient volunteer recruit 170 patient OSA . Eligibility randomization : The criterion ADHF admission diagnosis heart failure ; chief complaint dyspnea ; ejection fraction 45 % less . Additionally , elevate leave ventricular pressure indicate least one sign one symptom volume overload ( pedal edema , crackle , consistent chest X-ray , increased leave ventricular end-diastolic diameter , elevate BNP level ) require [ 46 ] .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<criteria>Previously unrecognized OSA Apnea Hypopnea Index ( AHI ) &gt; 15 event per hour attend inhospital sleep study . Patients apnea index less 5 event / hour exclude ( see design consideration rationale ) Projected length stay 3 day morning follow cardiorespiratory sleep study Ongoing plan target treatment heart failure include one following : IV diuretic , IV infusion inotropes vasodilator , plan revascularization , device therapy Patients already diagnose OSA Patients Central Sleep Apnea Patients diastolic heart failure Cardiogenic shock hemodynamic instability MAP le 55 mmHg vasopressor , concurrently vasopressor treatment , leave ventricular assist device , intraaortic Balloon Pump . Inotropic agent constitute exclusion criterion . Patients eligible vasopressor . Acute respiratory failure insufficiency define P/F ( PaO2/FIO2 ) ratio less 250 , FIO2 requirement 50 % Overt neurological deficit Renal failure require renal replacement therapy ; Patients exclude undergoing ultrafiltration volume removal Patients schedule procedure interfere post randomization measurement : This include schedule coronary bypass surgery , expect leave ventricular assist device placement . Patients arrive longterm care facility expect discharged one ; patient poor functional outcome preclude ability use CPAP device independently . Patients long term `` bridging '' inotropic infusion , short life expectancy due concomitant illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Obstructive Sleep Apnea</keyword>
	<keyword>OSA</keyword>
	<keyword>CHF</keyword>
	<keyword>Sleep apnea</keyword>
	<keyword>CHD</keyword>
</DOC>